Abbott to Acquire Surmodics for $2.7 Billion
| Field | Detail |
|---|---|
| Company | Surmodics Inc |
| Form Type | 8-K |
| Filed Date | Jul 2, 2025 |
| Risk Level | medium |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, merger, healthcare
Related Tickers: ABT
TL;DR
Abbott buying Surmodics for $2.7B ($47.50/share), deal expected to close early 2026.
AI Summary
Surmodics, Inc. announced on June 5, 2025, that it has entered into a definitive agreement to be acquired by Abbott Laboratories for $2.7 billion, or $47.50 per share. This transaction is expected to close in the first half of 2026, subject to customary closing conditions.
Why It Matters
This acquisition by a major player like Abbott Laboratories could significantly impact Surmodics' product development and market reach, potentially leading to new innovations in medical devices.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions and regulatory approvals, which could delay or prevent the deal from closing.
Key Numbers
- $2.7B — Acquisition Value (Total amount Abbott Laboratories is paying for Surmodics, Inc.)
- $47.50 — Price Per Share (Cash amount each Surmodics shareholder will receive per share.)
Key Players & Entities
- Surmodics, Inc. (company) — Company filing the report and being acquired
- Abbott Laboratories (company) — Acquiring company
- $2.7 billion (dollar_amount) — Total acquisition price
- $47.50 (dollar_amount) — Price per share
- June 05, 2025 (date) — Date of the earliest event reported
- first half of 2026 (date) — Expected closing period for the acquisition
FAQ
What is the primary reason for Abbott Laboratories acquiring Surmodics, Inc.?
The filing does not explicitly state the primary reason, but it is an acquisition agreement.
What is the total value of the transaction?
The total value of the transaction is $2.7 billion.
What is the price per share being offered to Surmodics shareholders?
Surmodics shareholders will receive $47.50 in cash per share.
When is the acquisition expected to be completed?
The acquisition is expected to close in the first half of 2026.
Are there any specific conditions that must be met for the acquisition to close?
Yes, the transaction is subject to customary closing conditions and regulatory approvals.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 2, 2025 regarding SURMODICS INC.